Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of oxyfedrine + sulfasalazine in advanced solid tumors
jRCT2031230531Phase 1Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of oxyfedrine and 5-aminosalicylic acid + sulphasalazine in Nonhematologic neoplasms, gastric cancer (GC), renal cell carcinoma (RCC) and 1 more (4 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Incidence of dose-limiting toxicities. Started Jan 2024; status: active, not recruiting.
02
Drugs
oxyfedrine5-aminosalicylic acid + sulphasalazine
03
Conditions
Nonhematologic neoplasmsgastric cancer (GC)renal cell carcinoma (RCC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on jRCT2031230531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230531.